Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 6/20 | 0.54 |
| ▸ | CA1 | P00915 | 6/20 | 0.54 |
| ▸ | CA2 | P00918 | 6/20 | 0.54 |
| ▸ | CA7 | P43166 | 6/20 | 0.54 |
| ▸ | CA9 | Q16790 | 6/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24379435 | 0.88 | CA12 (0.50) | CYP3A4ACHECA12CA1CA2 | |
| SCHEMBL18646092 | 0.87 | CYP3A4 (0.47) | CYP3A4ACHECA12CA1CA2 | |
| SCHEMBL1110779 | 0.84 | KMT2A (0.49) | CYP3A4ACHECA12CA1CA2 | |
| SCHEMBL12121020 | 0.83 | CYP3A4 (0.46) | CYP3A4ACHECA12CA1CA2 | |
| SCHEMBL522695 | 0.83 | KDM4E (0.57) | CYP3A4CA12CA1CA2CA7 | |
| SCHEMBL16896814 | 0.82 | CYP3A4 (0.44) | CYP3A4ACHECA12CA1CA2 | |
| SCHEMBL8665355 | 0.82 | CYP3A4 (0.42) | CYP3A4ACHECA12CA1CA2 | |
| SCHEMBL15525319 | 0.81 | MAPT (0.44) | CYP3A4ACHECA12CA1CA2 | |
| SCHEMBL517686 | 0.81 | NOTUM (0.47) | CYP3A4ACHECA12CA1CA2 | |
| SCHEMBL5967903 | 0.81 | GAA (0.43) | CYP3A4ACHECA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125362-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2026-05-07 | — | — | US | disclosed |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| CN-111699176-B | Quinazolinones as PARP14 inhibitors | 里邦医疗公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2024251205-A1 | QUINAZOLINONE DERIVATIVE AND MEDICAL USE THEREOF | 西藏海思科制药有限公司 | 2024-12-12 | — | — | WO | disclosed |
| CN-119101042-A | Quinazolinone derivative and application thereof in medicine | 西藏海思科制药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-11976067-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY | 2009-05-07 | — | — | US | disclosed |
| EP-1805169-B1 | HISTAMINE H3 RECEPTOR INHIBITORS, THEIR PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080058544-A1 | Liquid crystalline organic semiconductor material and organic semiconductor device using same | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2008-03-06 | — | — | US | disclosed |
| US-20080015235-A1 | Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses | JESUDASON CYNTHIA D | 2008-01-17 | — | — | US | disclosed |
| EP-1805169-A1 | HISTAMINE H3 RECEPTOR INHIBITORS, THEIR PREPARATION AND THERAPEUTIC USES | Eli Lilly and Company (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1756051-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006044228-A1 | HISTAMINE H3 RECEPTOR INHIBITORS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2005121080-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-22 | — | — | WO | disclosed |
| US-6149990-A | Carboxylate derivatives comprising an ether group and liquid crystal composition comprising the same | CHISSO CORPORATION (JP) | 2000-11-21 | — | — | US | disclosed |
| EP-0884302-A1 | CARBOXYLIC ESTER DERIVATIVES CONTAINING ETHER GROUP AND LIQUID-CRYSTAL COMPOSITION CONTAINING THE SAME | CHISSO CORPORATION (JP) | 1998-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | HRH3, HRH4, HCRTR1 | CYP3A4 911/4885ACHE 1028/4885CA12 4598/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | CYP3A4 1340/4885ACHE 1476/4885CA12 4394/4885 |
| US-20080058544-A1 | Liquid crystalline organic semiconductor material and organic semiconductor device using same | SLCO4C1, SLCO2A1, SLCO1A2 | CYP3A4 3287/4885ACHE 2187/4885CA12 2233/4885 |
| US-11976067-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, LDLR | CYP3A4 1435/4885ACHE 1536/4885CA12 4408/4885 |
| US-20260125362-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP16, PARP11 | CYP3A4 2737/4885ACHE 4865/4885CA12 4279/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | CYP3A4 1340/4885ACHE 1476/4885CA12 4394/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | CYP3A4 1340/4885ACHE 1476/4885CA12 4394/4885 |
| US-20080015235-A1 | Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses | HRH3, HRH4, HCRTR1 | CYP3A4 1580/4885ACHE 276/4885CA12 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.